Xtl Biopharma Ads (XTLB) 1.03 $XTLB
Promising Lupus Drug From XTL Biopharmaceuticals Could Be Life Changer In Projected $4 Billion Market
ACCESSWIRE - Thu Jun 02, 8:01AM CDT
NEW YORK, NY / ACCESSWIRE / June 2, 2016 / Lupus - invisible, silent; an autoimmune disease where the body's defenses mistakenly attack its own cells and living with lupus is never ending. Up to 5 million people, mainly women of childbearing age, suffer progression of this disorder because of diagnostic confusion. Most present with fever, malaise and facial skin rash suggesting to internists other unrelated health problems. A capricious disease, lupus strikes in skin, joints, kidney, heart, pancreas, colon, eyes, blood...the list continues and flare-ups are sporadic. If organ damage is severe, lupus can be fatal.
XTLB: 1.03 (-0.08), TEVA: 53.01 (-0.30), GSK: 40.93 (-1.13)
XTL Biopharmaceuticals Reports First Quarter 2016 Financial Results & Provides Clinical and Operational Update
PR Newswire - Wed Jun 01, 7:30AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"
, a clinical-stage biopharmaceutical company developing its lead product for the treatment of lupus, today announced financial results for the three months ended March 31, 2016 and provided an update on the development program for its lead drug candidate hCDR1 in the treatment of Systemic Lupus Erythematosus (SLE).
XTLB: 1.03 (-0.08)
XTL Biopharmaceuticals to Present at ChinaBio Partnering Forum 2016 in Suzhou, China on May 19, 2016
PR Newswire - Mon May 16, 10:45AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company", a clinical-stage biopharmaceutical company developing its lead product for the treatment of lupus, announced today the Company's CEO Josh Levine will be presenting at the ChinaBio® Partnering Forum in Suzhou, China on Thursday, May 19, 2016 at 2:00 PM.
XTLB: 1.03 (-0.08)
XTL Biopharmaceuticals Reports 2015 Financial Results & Provides Clinical and Operational Update
PR Newswire - Thu Mar 31, 8:45AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company", a clinical-stage biopharmaceutical company developing its lead product for the treatment of lupus, today announced financial results for the year ended December 31, 2015 and provided an update on the development program for its lead drug candidate hCDR1.
XTLB: 1.03 (-0.08)
XTL Biopharmaceuticals Completes Phase 2 Trial Design for Lead Compound hCDR1 in the Treatment of Lupus
PR Newswire - Mon Mar 21, 7:30AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company", a clinical-stage biopharmaceutical company developing its lead product for the treatment of lupus, today announced it has completed the clinical trial design for its upcoming Phase 2 study of hCDR1 in the treatment of systemic lupus erythematosus (SLE). The global study is planned to commence in 2016, following the Company's investigational new drug (IND) filing with the U.S. Food and Drug Administration (FDA).
XTLB: 1.03 (-0.08)
XTL Biopharmaceuticals' Lupus Drug hCDR1 Granted Patent for Pharmaceutical Composition & Manufacturing Processes
PR Newswire - Wed Feb 10, 7:30AM CST
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company", a clinical-stage biopharmaceutical company developing its lead product for the treatment of lupus, today announced that its lead drug candidate hCDR1 has been granted a patent by the Israel Patent Office. The patent, titled "Pharmaceutical Compositions Comprising a Peptide and a Substituted ß Cyclodextrin for use in Treating Systemic Lupus Erythematosus and Processes for their Manufacture," addresses the pharmaceutical composition of hCDR1 and its manufacturing processes. The compound hCDR1 and its formulations have been previously granted patents in numerous key jurisdictions including the U.S., Europe, Israel, Japan, China, India, Russia, Australia and Canada.
XTLB: 1.03 (-0.08)
XTL Biopharmaceuticals Joins Corporate Advisory Council of the Lupus Foundation of America
PR Newswire - Wed Jan 27, 7:30AM CST
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB) ("XTL" or the "Company", a clinical-stage biopharmaceutical company developing its lead product for the treatment of lupus, today announced that it has accepted the Lupus Foundation of America's (LFA) invitation to join the foundation's Corporate Advisory Council (CAC) as of January 2016.
XTLB: 1.03 (-0.08)
XTL Biopharmaceuticals Advances Formulation of its hCDR1 Drug for Clinical Trials in the Treatment of Lupus Through use of Cydex Pharmaceuticals' Captisol®
PR Newswire - Wed Jan 13, 7:30AM CST
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company", a clinical-stage biopharmaceutical company developing its lead product for the treatment of lupus, today announced that it has reached agreement with CyDex Pharmaceuticals Inc. (La Jolla, CA) (CyDex) for the use and supply of Captisol® in the formulation of its lead drug, hCDR1, for the treatment of systemic lupus erythematosus (SLE).
XTL: 58.29 (-0.50), XTLB: 1.03 (-0.08)
XTL Biopharmaceuticals Submits Protocol to Yeda for Advanced Clinical Trial of hCDR1 in the Treatment of Lupus
PR Newswire - Mon Jan 11, 7:30AM CST
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company", a clinical-stage biopharmaceutical company developing its lead product for the treatment of lupus, today announced that it has submitted the full protocol for its advanced stage clinical trial of hCDR1 for the treatment of systemic lupus erythematosus (SLE) to Yeda Research and Development Company Ltd. (Yeda).
XTL: 58.29 (-0.50), XTLB: 1.03 (-0.08)
Cellect Biomed Announces Key Leadership Changes
GlobeNewswire - Mon Nov 09, 7:30AM CST
Cellect Biomed Ltd. (TASE:CLBD) ("Cellect" or the "Company", a developer of innovative technology which enables the functional selection of stem cells, announced additions to its management and professional teams in support of its preparations for the commencement of human clinical trials and its planned dual-listing on a U.S. stock exchange.
XTLB: 1.03 (-0.08), ORPN: 1.93 (-0.05)
XTL Biopharmaceuticals to Present at BIO-Europe 2015 in Munich, Germany on November 3rd, 2015
PR Newswire - Mon Oct 26, 8:15AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company", a clinical-stage biopharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of unmet clinical needs with a focus on treatments for autoimmune diseases, announced today that its Chief Executive Officer, Josh Levine, will be presenting at BIO-Europe 2015, being held at the International Congress Center (ICM) in Munich, Germany.
XTL: 58.29 (-0.50), XTLB: 1.03 (-0.08)
XTL Biopharmaceuticals Announces Agreement With Yeda Research and Development Company Ltd. to Amend License Agreement for Lupus Asset
PR Newswire - Tue Oct 13, 7:45AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company", a clinical-stage biopharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of unmet clinical needs with a focus on treatments for autoimmune diseases, today announced that it has reached agreement with Yeda Research and Development Company Ltd. ("Yeda" to amend the development milestones in the License Agreement signed between the parties in January 2014 for the development of hCDR1 for the treatment of systemic lupus erythematosus (SLE).
XTL: 58.29 (-0.50), XTLB: 1.03 (-0.08)
XTL Biopharmaceuticals to Present at the Rodman & Renshaw 17th Annual Global Investment Conference on September 10th 2015 at the St. Regis Hotel in NYC
PR Newswire - Thu Sep 03, 8:00AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company", a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, announced today that its Chief Executive Officer, Josh Levine, will be presenting at The Rodman & Renshaw 17th Annual Global Investment Conference being held at the St. Regis Hotel in New York.
XTL: 58.29 (-0.50), XTLB: 1.03 (-0.08)
XTL Biopharmaceuticals Reports Second Quarter 2015 Results
PR Newswire - Tue Sep 01, 8:00AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company", a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, today provided its financial and operational results for the second quarter and the six months ended June 30, 2015.
XTL: 58.29 (-0.50), XTLB: 1.03 (-0.08), NVS: 78.94 (-1.57)
XTL Biopharmaceuticals Provides First Quarter 2015 Financial Update and Announces Focus of Efforts on its Lupus and Multiple Myeloma Assets
PR Newswire - Mon Jun 01, 7:00AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company", a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, today announced that following an evaluation of the market opportunity for it pipeline products, the Company has decided to focus its efforts and expenditures exclusively on its two core assets: hCDR1 for the treatment of SLE/lupus and rHuEPO for "no-option" multiple myeloma patients. XTL also provided its financial and operational results for the first quarter ended March 31, 2015.
XTL: 58.29 (-0.50), XTLB: 1.03 (-0.08)
Earnings Update: Complementary Research on Tantech Holdings, Sypris Solutions, Swisher Hygiene, XTL Biopharmaceuticals, ADMA Biologics
PR Newswire - Mon May 18, 7:40AM CDT
Editor Note: For more information about this release, please scroll to bottom.
SYPR: 1.04 (+0.05), TANH: 4.40 (+0.10), ADMA: 7.24 (-0.21), XTLB: 1.03 (-0.08)
XTL Biopharmaceuticals to Present at IATI Biomed 2015 Conference
PR Newswire - Mon May 11, 10:59AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company", a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, announced today that the company will present at the IATI Biomed 2015 Conference on May 12, 2015:
XTL: 58.29 (-0.50), XTLB: 1.03 (-0.08)
Promising Lupus Drug From XTL Biopharmaceuticals Could Be Life Changer In Projected $4 Billion Market
ACCESSWIRE - Thu Jun 02, 8:01AM CDT
NEW YORK, NY / ACCESSWIRE / June 2, 2016 / Lupus - invisible, silent; an autoimmune disease where the body's defenses mistakenly attack its own cells and living with lupus is never ending. Up to 5 million people, mainly women of childbearing age, suffer progression of this disorder because of diagnostic confusion. Most present with fever, malaise and facial skin rash suggesting to internists other unrelated health problems. A capricious disease, lupus strikes in skin, joints, kidney, heart, pancreas, colon, eyes, blood...the list continues and flare-ups are sporadic. If organ damage is severe, lupus can be fatal.
XTLB: 1.03 (-0.08), TEVA: 53.01 (-0.30), GSK: 40.93 (-1.13)
XTL Biopharmaceuticals Reports First Quarter 2016 Financial Results & Provides Clinical and Operational Update
PR Newswire - Wed Jun 01, 7:30AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"
, a clinical-stage biopharmaceutical company developing its lead product for the treatment of lupus, today announced financial results for the three months ended March 31, 2016 and provided an update on the development program for its lead drug candidate hCDR1 in the treatment of Systemic Lupus Erythematosus (SLE). XTLB: 1.03 (-0.08)
XTL Biopharmaceuticals to Present at ChinaBio Partnering Forum 2016 in Suzhou, China on May 19, 2016
PR Newswire - Mon May 16, 10:45AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"
, a clinical-stage biopharmaceutical company developing its lead product for the treatment of lupus, announced today the Company's CEO Josh Levine will be presenting at the ChinaBio® Partnering Forum in Suzhou, China on Thursday, May 19, 2016 at 2:00 PM. XTLB: 1.03 (-0.08)
XTL Biopharmaceuticals Reports 2015 Financial Results & Provides Clinical and Operational Update
PR Newswire - Thu Mar 31, 8:45AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"
, a clinical-stage biopharmaceutical company developing its lead product for the treatment of lupus, today announced financial results for the year ended December 31, 2015 and provided an update on the development program for its lead drug candidate hCDR1. XTLB: 1.03 (-0.08)
XTL Biopharmaceuticals Completes Phase 2 Trial Design for Lead Compound hCDR1 in the Treatment of Lupus
PR Newswire - Mon Mar 21, 7:30AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"
, a clinical-stage biopharmaceutical company developing its lead product for the treatment of lupus, today announced it has completed the clinical trial design for its upcoming Phase 2 study of hCDR1 in the treatment of systemic lupus erythematosus (SLE). The global study is planned to commence in 2016, following the Company's investigational new drug (IND) filing with the U.S. Food and Drug Administration (FDA). XTLB: 1.03 (-0.08)
XTL Biopharmaceuticals' Lupus Drug hCDR1 Granted Patent for Pharmaceutical Composition & Manufacturing Processes
PR Newswire - Wed Feb 10, 7:30AM CST
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"
, a clinical-stage biopharmaceutical company developing its lead product for the treatment of lupus, today announced that its lead drug candidate hCDR1 has been granted a patent by the Israel Patent Office. The patent, titled "Pharmaceutical Compositions Comprising a Peptide and a Substituted ß Cyclodextrin for use in Treating Systemic Lupus Erythematosus and Processes for their Manufacture," addresses the pharmaceutical composition of hCDR1 and its manufacturing processes. The compound hCDR1 and its formulations have been previously granted patents in numerous key jurisdictions including the U.S., Europe, Israel, Japan, China, India, Russia, Australia and Canada. XTLB: 1.03 (-0.08)
XTL Biopharmaceuticals Joins Corporate Advisory Council of the Lupus Foundation of America
PR Newswire - Wed Jan 27, 7:30AM CST
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB) ("XTL" or the "Company"
, a clinical-stage biopharmaceutical company developing its lead product for the treatment of lupus, today announced that it has accepted the Lupus Foundation of America's (LFA) invitation to join the foundation's Corporate Advisory Council (CAC) as of January 2016. XTLB: 1.03 (-0.08)
XTL Biopharmaceuticals Advances Formulation of its hCDR1 Drug for Clinical Trials in the Treatment of Lupus Through use of Cydex Pharmaceuticals' Captisol®
PR Newswire - Wed Jan 13, 7:30AM CST
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"
, a clinical-stage biopharmaceutical company developing its lead product for the treatment of lupus, today announced that it has reached agreement with CyDex Pharmaceuticals Inc. (La Jolla, CA) (CyDex) for the use and supply of Captisol® in the formulation of its lead drug, hCDR1, for the treatment of systemic lupus erythematosus (SLE). XTL: 58.29 (-0.50), XTLB: 1.03 (-0.08)
XTL Biopharmaceuticals Submits Protocol to Yeda for Advanced Clinical Trial of hCDR1 in the Treatment of Lupus
PR Newswire - Mon Jan 11, 7:30AM CST
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"
, a clinical-stage biopharmaceutical company developing its lead product for the treatment of lupus, today announced that it has submitted the full protocol for its advanced stage clinical trial of hCDR1 for the treatment of systemic lupus erythematosus (SLE) to Yeda Research and Development Company Ltd. (Yeda). XTL: 58.29 (-0.50), XTLB: 1.03 (-0.08)
Cellect Biomed Announces Key Leadership Changes
GlobeNewswire - Mon Nov 09, 7:30AM CST
Cellect Biomed Ltd. (TASE:CLBD) ("Cellect" or the "Company"
, a developer of innovative technology which enables the functional selection of stem cells, announced additions to its management and professional teams in support of its preparations for the commencement of human clinical trials and its planned dual-listing on a U.S. stock exchange. XTLB: 1.03 (-0.08), ORPN: 1.93 (-0.05)
XTL Biopharmaceuticals to Present at BIO-Europe 2015 in Munich, Germany on November 3rd, 2015
PR Newswire - Mon Oct 26, 8:15AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"
, a clinical-stage biopharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of unmet clinical needs with a focus on treatments for autoimmune diseases, announced today that its Chief Executive Officer, Josh Levine, will be presenting at BIO-Europe 2015, being held at the International Congress Center (ICM) in Munich, Germany. XTL: 58.29 (-0.50), XTLB: 1.03 (-0.08)
XTL Biopharmaceuticals Announces Agreement With Yeda Research and Development Company Ltd. to Amend License Agreement for Lupus Asset
PR Newswire - Tue Oct 13, 7:45AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"
, a clinical-stage biopharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of unmet clinical needs with a focus on treatments for autoimmune diseases, today announced that it has reached agreement with Yeda Research and Development Company Ltd. ("Yeda" to amend the development milestones in the License Agreement signed between the parties in January 2014 for the development of hCDR1 for the treatment of systemic lupus erythematosus (SLE). XTL: 58.29 (-0.50), XTLB: 1.03 (-0.08)
XTL Biopharmaceuticals to Present at the Rodman & Renshaw 17th Annual Global Investment Conference on September 10th 2015 at the St. Regis Hotel in NYC
PR Newswire - Thu Sep 03, 8:00AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"
, a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, announced today that its Chief Executive Officer, Josh Levine, will be presenting at The Rodman & Renshaw 17th Annual Global Investment Conference being held at the St. Regis Hotel in New York. XTL: 58.29 (-0.50), XTLB: 1.03 (-0.08)
XTL Biopharmaceuticals Reports Second Quarter 2015 Results
PR Newswire - Tue Sep 01, 8:00AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"
, a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, today provided its financial and operational results for the second quarter and the six months ended June 30, 2015. XTL: 58.29 (-0.50), XTLB: 1.03 (-0.08), NVS: 78.94 (-1.57)
XTL Biopharmaceuticals Provides First Quarter 2015 Financial Update and Announces Focus of Efforts on its Lupus and Multiple Myeloma Assets
PR Newswire - Mon Jun 01, 7:00AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"
, a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, today announced that following an evaluation of the market opportunity for it pipeline products, the Company has decided to focus its efforts and expenditures exclusively on its two core assets: hCDR1 for the treatment of SLE/lupus and rHuEPO for "no-option" multiple myeloma patients. XTL also provided its financial and operational results for the first quarter ended March 31, 2015. XTL: 58.29 (-0.50), XTLB: 1.03 (-0.08)
Earnings Update: Complementary Research on Tantech Holdings, Sypris Solutions, Swisher Hygiene, XTL Biopharmaceuticals, ADMA Biologics
PR Newswire - Mon May 18, 7:40AM CDT
Editor Note: For more information about this release, please scroll to bottom.
SYPR: 1.04 (+0.05), TANH: 4.40 (+0.10), ADMA: 7.24 (-0.21), XTLB: 1.03 (-0.08)
XTL Biopharmaceuticals to Present at IATI Biomed 2015 Conference
PR Newswire - Mon May 11, 10:59AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"
, a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, announced today that the company will present at the IATI Biomed 2015 Conference on May 12, 2015: XTL: 58.29 (-0.50), XTLB: 1.03 (-0.08)
